Sponsor or institution
Clinical trials and research at TORL Biotherapeutics, LLC
As of November 12, 2026, Find a Trial lists 4 clinical trials run by TORL Biotherapeutics, LLC that are recruiting, at sites in 12 countries (most in United States (4), South Korea (2), Australia (1)). By phase: Phase 1/2 (2), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 12Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| TORL-5-700 in relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1/2 | Fullerton, California and 8 other locations | Recruiting | Feb 27, 2026 |
| Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer | Phase 1/2 | Fullerton, California and 6 other locations | Recruiting | Jan 7, 2026 |
| Evaluating TORL-1-23 for advanced platinum-resistant ovarian cancer | Phase 2 | Phoenix, Arizona and 65 other locations | Recruiting | Nov 15, 2024 |
| Testing TORL-1-23 in patients with advanced cancer | Phase 1 | Fullerton, California and 13 other locations | Recruiting | Nov 2, 2021 |
All recruiting trials (4)
-
TORL-5-700 in relapsed or refractory B-cell non-Hodgkin lymphoma
This study tests TORL-5-700 alone and with another drug to see if it helps people with relapsed or refractory B-cell non-Hodgkin lymphoma.
-
Giving TORL-1-23 with chemotherapy before initial surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer
This study will test whether adding TORL-1-23 to standard paclitaxel and carboplatin before initial surgery helps women with advanced (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer whose tumors are CLDN6-positive.
-
Evaluating TORL-1-23 for advanced platinum-resistant ovarian cancer
This study is testing a new treatment called TORL-1-23 for women with advanced ovarian cancer that doesn't respond to standard platinum-based therapies to see if it can help them.
-
Testing TORL-1-23 in patients with advanced cancer
This study is testing a new treatment called TORL-1-23 to see if it can help people with advanced cancers like ovarian, endometrial, and lung cancer feel better and fight their disease.
Quick answers
How many clinical trials run by TORL Biotherapeutics, LLC are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 12 countries. The most sites are in United States (4 trials), South Korea (2 trials), Australia (1 trial), Austria (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.